New cell therapy aims to reduce chemo side effects for rare blood disease
NCT ID NCT04784052
First seen Jan 30, 2026 · Last updated May 14, 2026 · Updated 11 times
Summary
This study tests a new way to treat Fanconi Anemia, a rare genetic disorder that causes bone marrow failure. Instead of standard high-dose chemotherapy, patients receive donor stem cells that have been specially filtered to remove certain immune cells, along with an experimental antibody called JSP191. The goal is to help the donor cells grow in the patient's body with fewer severe side effects. About 18 participants will be followed for up to 2 years after the transplant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FANCONI ANEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Stanford University
RECRUITINGStanford, California, 94305, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.